Stifel analyst Bradley Canino reiterated a Buy rating and $70.00 price target on Janux Therapeutics (NASDAQ: JANX).The analyst comments "Updated ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Janux Therapeutics (JANX) PT Raised to $115 at StifelDecember 3, 2024 8:22 AM William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'December 3, 2024 7:06 AM Janux Therapeutics (JANX) PT Raised to $91 at Leerink PartnersDecember 3, 2024 6:55 AM Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'December 3, 2024 5:26 AM Form 8-K Janux Therapeutics, Inc. For: Dec 02December 2, 2024 5:12 PM Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX)December 2, 2024 4:41 PM Janux Therapeutics (JANX) Surges 40% After Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCDecember 2, 2024 4:40 PM After-hours movers: Zscaler, Honeywell, Microchip Technology and moreDecember 2, 2024 4:38 PM Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCDecember 2, 2024 4:34 PM Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCDecember 2, 2024 4:30 PM